Treatment of keloids with a single dose of low-energy superficial X-ray radiation to prevent recurrence after surgical excision: An in vitro and in vivo study - 10/10/20
, Akash Gunjan, PhD a, ⁎ Abstract |
Background |
Although keloids have been empirically treated with steroids and radiation, evidence-based radiation parameters for keloid therapy are lacking.
Objective |
To determine evidence-based radiation parameters for blocking keloid fibroblast proliferation in vitro and apply them to patients.
Methods |
The effects of various radiation parameters and steroids on cell proliferation, cell death, and collagen production in keloid explants and fibroblasts were evaluated with standard assays. Effective radiation parameters were then tested on patients.
Results |
No differences were observed between the effects of 50 and 320 kV radiation or between single and fractionated radiation doses on keloid fibroblasts. A 3 Gy, 50 kV dose inhibited keloid fibroblast proliferation in culture, whereas 9 Gy completely blocked their outgrowth from explants by inducing multiple cell death pathways and reducing collagen levels. Thirteen of 14 keloids treated with a single 8 Gy, 50 kV dose of radiation did not recur, although 4 patients with 6 keloids were lost to follow-up.
Limitations |
Seventy-five percent of patients received steroids for pruritus, whereas approximately 25% of patients were lost to follow-up.
Conclusions |
A single 8 Gy dose of superficial 50 kV radiation delivered an average of 34 days after keloid excision maybe sufficient to minimize recurrence, including in individuals resistant to steroids. Higher radiation energies, doses, or fractions may be unnecessary for keloid therapy.
Le texte complet de cet article est disponible en PDF.Graphical abstract |
Key words : collagen, explant, fibroblast, keloid, radiation, radiotherapy, recurrence, steroid, treatment schedule, triamcinolone
Plan
| Authors Son and Phillips contributed equally to this article. |
|
| Funding sources: Supported by the Florida State University College of Medicine (Dr Gunjan). |
|
| Conflicts of interest: None disclosed. |
|
| IRB approval status: Approved by the Human Subjects Committee of the Florida State University Institutional Review Board (2016.19175 and 2017.22173). |
Vol 83 - N° 5
P. 1304-1314 - novembre 2020 Retour au numéro
Article précédent
- Evaluation of platelet-rich plasma as a treatment for androgenetic alopecia: A randomized controlled trial
- Jerry Shapiro, Anthony Ho, Kumar Sukhdeo, Lu Yin, Kristen Lo Sicco
- Multicenter prospective study on multivariant diagnostics of autoimmune bullous dermatoses using the BIOCHIP technology
- Nina van Beek, Stine Krüger, Tarek Fuhrmann, Susanne Lemcke, Stephanie Goletz, Christian Probst, Lars Komorowski, Giovanni Di Zenzo, Marian Dmochowski, Kossara Drenovska, Michael Horn, Hana Jedlickova, Cezary Kowalewski, Ljiljana Medenica, Dedee Murrell, Aikaterini Patsatsi, Shamir Geller, Soner Uzun, Snejina Vassileva, Xuejun Zhu, Kai Fechner, Detlef Zillikens, Winfried Stöcker, Enno Schmidt, Kristin Rentzsch
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?